Strategies to prevent anthracycline-related congestive heart failure in survivors of childhood cancer

Cardiology Research and Practice

Volumn 1, Issue 1, 2012, Pages

  Armenian, Saro H ^a   Gelehrter, Sarah K ^b   Chow, Eric J ^c,d  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d SEATTLE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CARVEDILOL; DAUNORUBICIN; DOXORUBICIN; ENALAPRIL; EPIRUBICIN; IDARUBICIN; MITOXANTRONE; PERINDOPRIL; PLACEBO; RAZOXANE;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CANCER SURVIVOR; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CHILD; CHILDHOOD CANCER; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; LYMPHOMA; METASTASIS; MUSCULOSKELETAL DISEASE; OUTCOME ASSESSMENT; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION;

EID: 84866246273     PISSN: None     EISSN: 20900597     Source Type: Journal    
DOI: 10.1155/2012/713294     Document Type: Review

References (65)

1. Lipshultz S. E., Alvarez J. A., Scully R. E., Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008 94 4 525 533 2-s2.0-41149115636 10.1136/hrt.2007.136093
2. Howlader N., Noone A. M., Krapcho M., SEER Cancer Statistics Review, 19752008 Bethesda, Md, USA National Cancer Institute
3. Yahalom J., Portlock C. S., Long-term cardiac and pulmonary complications of cancer therapy. Hematology/Oncology Clinics of North America 2008 22 2 305 318 2-s2.0-41349109949 10.1016/j.hoc.2008.01.010
4. Lipshultz S. E., Lipsitz S. R., Sallan S. E., Dalton V. M., Mone S. M., Gelber R. D., Colan S. D., Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. Journal of Clinical Oncology 2005 23 12 2629 2636 2-s2.0-18444416815 10.1200/JCO.2005.12. 121
5. van Dalen E. C., van der Pal H. J. H., Kok W. E. M., Caron H. N., Kremer L. C. M., Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. European Journal of Cancer 2006 42 18 3191 3198 2-s2.0-33845328492 10.1016/j.ejca.2006.08.005
6. Adams M. J., Lipshultz S. E., Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatric Blood and Cancer 2005 44 7 600 606 2-s2.0-18244372155 10.1002/pbc.20352
7. Giantris A., Abdurrahman L., Hinkle A., Asselin B., Lipshultz S. E., Anthracycline-induced cardiotoxicity in children and young adults. Critical Reviews in Oncology/Hematology 1998 27 1 53 68 2-s2.0-0001115439 10.1016/S1040-8428(97)10007-5
8. Kremer L. C. M., van Dalen E. C., Offringa M., Voûte P. A., Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Annals of Oncology 2002 13 4 503 512 2-s2.0-0036237672 10.1093/annonc/mdf118
9. Meacham L. R., Chow E. J., Ness K. K., Kamdar K. Y., Chen Y., Yasui Y., Oeffinger K. C., Sklar C. A., Robison L. L., Mertens A. C., Cardiovascular risk factors in adult survivors of pediatric cancer-a report from the childhood cancer survivor study. Cancer Epidemiology Biomarkers and Prevention 2010 19 1 170 181 2-s2.0-74549203194 10.1158/1055-9965.EPI-09-0555
10. Felker G. M., Thompson R. E., Hare J. M., Hruban R. H., Clemetson D. E., Howard D. L., Baughman K. L., Kasper E. K., Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. New England Journal of Medicine 2000 342 15 1077 1084 2-s2.0-0034643399 10.1056/ NEJM200004133421502
11. Krischer J. P., Epstein S., Cuthbertson D. D., Goorin A. M., Epstein M. L., Lipshultz S. E., Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. Journal of Clinical Oncology 1997 15 4 1544 1552 2-s2.0-0030904457
12. Hunt S. A., Abraham W. T., Chin M. H., Feldman A. M., Francis G. S., Ganiats T. G., Jessup M., Konstam M. A., Mancini D. M., Michl K., Oates J. A., Rahko P. S., Silver M. A., Stevenson L. W., Yancy C. W., Antman E. M., Smith S. C., Adams C. D., Anderson J. L., Faxon D. P., Fuster V., Halperin J. L., Hiratzka L. F., Jacobs A. K., Nishimura R., Ornato J. P., Page R. L., Riegel B., ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation 2005 112 12 e154 e235 2-s2.0-28744446343
13. Barry E. V., Lipshultz S. E., Sallan S. E., Anthracycline-induced cardiotoxicity: natural history, risk factors, and prevention. American Society of Clinical Oncology 2008 Chicago, Ill, USA
14. van Dalen E. C., van der Pal H. J., Caron H. N., Kremer L. C., Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database of Systematic Reviews 2009 7 4 CD005008 2-s2.0-75349085187
15. van Dalen E. C., Caron H. N., Dickinson H. O., Kremer L. C., Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database of Systematic Reviews 2008 2 CD003917 2-s2.0-44949174094
16. Smith L. A., Cornelius V. R., Plummer C. J., Levitt G., Verrill M., Canney P., Jones A., Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010 10, article 337 2-s2.0-77953931502 10.1186/1471-2407-10-337
17. van Dalen E. C., Michiels E. M., Caron H. N., Kremer L. C., Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database of Systematic Reviews 2010 3 CD005006 2-s2.0-77951248352
18. Zinzani P. L., Martelli M., Storti S., Musso M., Cantonetti M., Leone G., Cajozzo A., Papa G., Iannitto E., Perrotti A., Bendandi M., Gherlinzoni F., Gentilini P., Rossi G., Aitini E., Mandelli E., Tura S., Phase III comparative trial using CHOP versus CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma. Leukemia and Lymphoma 1995 19 3-4 329 335 2-s2.0-0029087420
19. Federico M., Clò V., Brugiatelli M., Carotenuto M., Gobbi P. G., Vallisa D., Lombardo M., Avanzini P., di Renzo N., Dini D., Baldini L., Silingardi V., Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL. Haematologica 1998 83 9 800 811 2-s2.0-0031763578
20. Ewer M. S., Cardiac safety of liposomal anthracyclines. Seminars in Oncology 2004 31 supplement 13 6 161 181 10.1053/j.seminoncol.2004.08.006
21. Minotti G., Recalcati S., Menna P., Salvatorelli E., Corna G., Cairo G., Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms. Methods in Enzymology 2004 378 340 361 2-s2.0-1342283083 10.1016/S0076-6879(04)78025-8
22. Lipshultz S. E., Giantris A. L., Lipsitz S. R., Dalton V. K., Asselin B. L., Barr R. D., Clavell L. A., Hurwitz C. A., Moghrabi A., Samson Y., Schorin M. A., Gelber R. D., Sallan S. E., Colan S. D., Doxorubicin administration by continuous infusion is not cardioprotective: The Dana-Farber 91-01 acute lymphoblastic leukemia protocol. Journal of Clinical Oncology 2002 20 6 1677 1682 2-s2.0-0037087687 10.1200/JCO.20.6.1677
23. Levitt G. A., Dorup I., Sorensen K., Sullivan I., Does anthracycline administration by infusion in children affect late cardiotoxicity? British Journal of Haematology 2004 124 4 463 468 2-s2.0-1242292932 10.1111/j.1365-2141. 2004.04803.x
24. Lipshultz S. E., Rifai N., Dalton V. M., Levy D. E., Silverman L. B., Lipsitz S. R., Colan S. D., Asselin B. L., Barr R. D., Clavell L. A., Hurwitz C. A., Moghrabi A., Samson Y., Schorin M. A., Gelber R. D., Sallan S. E., The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. New England Journal of Medicine 2004 351 2 145 153 2-s2.0-3042850886 10.1056/NEJMoa035153
25. Wexler L. H., Andrich M. P., Venzon D., Berg S. L., Weaver-McClure L., Chen C. C., Dilsizian V., Avila N., Jarosinski P., Balis F. M., Poplack D. G., Horowitz M. E., Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. Journal of Clinical Oncology 1996 14 2 362 372 2-s2.0-9044233260
26. Lipshultz S. E., Scully R. E., Lipsitz S. R., Sallan S. E., Silverman L. B., Miller T. L., Barry E. V., Asselin B. L., Athale U., Clavell L. A., Larsen E., Moghrabi A., Samson Y., Michon B., Schorin M. A., Cohen H. J., Neuberg D. S., Orav E. J., Colan S. D., Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. The Lancet Oncology 2010 11 10 950 961 2-s2.0-77957355941 10.1016/S1470-2045(10)70204-7
27. Tebbi C. K., London W. B., Friedman D., Villaluna D., De Alarcon P. A., Constine L. S., Mendenhall N. P., Sposto R., Chauvenet A., Schwartz C. L., Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. Journal of Clinical Oncology 2007 25 5 493 500 2-s2.0-33947542048 10.1200/JCO.2005.02.3879
28. Barry E. V., Vrooman L. M., Dahlberg S. E., Neuberg D. S., Asselin B. L., Athale U. H., Clavell L. A., Larsen E. C., Moghrabi A., Samson Y., Schorin M. A., Cohen H. J., Lipshultz S. E., Sallan S. E., Silverman L. B., Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. Journal of Clinical Oncology 2008 26 7 1106 1111 2-s2.0-41949096690 10.1200/JCO.2007.12.2481
29. Hellmann K., Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without evidence. Journal of Clinical Oncology 2007 25 29 4689 4690 2-s2.0-35648964243 10.1200/JCO.2007.12.6888
30. Vrooman L. M., Neuberg D. S., Stevenson K. E., Asselin B. L., Athale U. H., Clavell L., Cole P. D., Kelly K. M., Larsen E. C., Laverdire C., Michon B., Schorin M., Schwartz C. L., Cohen H. J., Lipshultz S. E., Silverman L. B., Sallan S. E., The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. European Journal of Cancer 2011 47 9 1373 1379 2-s2.0-79957557043 10.1016/j.ejca.2011.03.022
31. Hensley M. L., Hagerty K. L., Kewalramani T., Green D. M., Meropol N. J., Wasserman T. H., Cohen G. I., Emami B., Gradishar W. J., Brian Mitchell R., Thigpen J. T., Trotti A., Von Hoff D., Schuchter L. M., American society of clinical oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. Journal of Clinical Oncology 2009 27 1 127 145 2-s2.0-58149335531 10.1200/JCO.2008.17.2627
32. Bryant J., Picot J., Levitt G., Sullivan I., Baxter L., Clegg A., Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review. Health Technology Assessment 2007 11 27 1 84 2-s2.0-34547878004
33. Lokich J. J., Moore C. L., Anderson N. R., Comparison of costs for infusion versus bolus chemotherapy administrationpart two: use charges versus reimbursements for cost basis. Cancer 1996 78 2 300 303 2-s2.0-0030037491 10.1002/(SICI)1097-0142(19960715)78:2300::AID-CNCR17>3.0.CO;2-#
34. Visscher H., Ross C. J., Rassekh S. R., Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. Journal of Clinical Oncology 2012 30 13 1422 1428 10.1200/JCO.2010.34.3467
35. Blanco J. G., Sun C. L., Landier W., Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase Genesa report from the children's oncology group. Journal of Clinical Oncology 2012 30 13 1415 1421 10.1200/JCO.2011.34.8987
36. Children's Oncology Group, Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancers. 3. 0 ed 2008 Arcadia, Calif, USA Children's Oncology Group
37. Ewer M. S., Lenihan D. J., Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? Journal of Clinical Oncology 2008 26 8 1201 1203 2-s2.0-41649103274 10.1200/JCO.2007.14.8742
38. Gianni L., Herman E. H., Lipshultz S. E., Minotti G., Sarvazyan N., Sawyer D. B., Anthracycline cardiotoxicity: from bench to bedside. Journal of Clinical Oncology 2008 26 22 3777 3784 2-s2.0-49249135889 10.1200/JCO.2007.14. 9401
39. Kannel W. B., Incidence and epidemiology of heart failure. Heart Failure Reviews 2000 5 2 167 173 2-s2.0-0033838655 10.1023/A:1009884820941
40. Herman E. H., El-Hage A. N., Ferrans V. J., Ardalan B., Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats. Toxicology and Applied Pharmacology 1985 78 2 202 214 2-s2.0-0021814289
41. Giles T. D., Sander G. E., Diabetes mellitus and heart failure: basic mechanisms, clinical features, and therapeutic considerations. Cardiology Clinics 2004 22 4 553 568 2-s2.0-6344292507 10.1016/j.ccl.2004.07.002
42. Armenian S. H., Sun C.-L., Shannon T., Mills G., Francisco L., Venkataraman K., Wong F. L., Forman S. J., Bhatia S., Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. Blood 2011 118 23 6023 6029 2-s2.0-82955207669 10.1182/blood-2011-06-358226
43. Silber J. H., Cnaan A., Clark B. J., Paridon S. M., Chin A. J., Rychik J., Hogarty A. N., Cohen M. I., Barber G., Rutkowski M., Kimball T. R., Delaat C., Steinherz L. J., Zhao H., Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. Journal of Clinical Oncology 2004 22 5 820 828 2-s2.0-1542608355 10.1200/JCO.2004.06.022
44. Connuck D. M., Sleeper L. A., Colan S. D., Cox G. F., Towbin J. A., Lowe A. M., Wilkinson J. D., Orav E. J., Cuniberti L., Salbert B. A., Lipshultz S. E., Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. American Heart Journal 2008 155 6 998 1005 2-s2.0-44349129859 10.1016/j.ahj.2008.01.018
45. Duboc D., Meune C., Pierre B., Wahbi K., Eymard B., Toutain A., Berard C., Vaksmann G., Weber S., Bécane H. M., Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up. American Heart Journal 2007 154 3 596 602 2-s2.0-34547934811 10.1016/j.ahj.2007.05.014
46. Fleming T. R., Surrogate end points in cardiovascular disease trials. American Heart Journal 2000 139 4 S193 S196 2-s2.0-0034126842
47. Anand I. S., Florea V. G., Fisher L., Surrogate end points in heart failure. Journal of the American College of Cardiology 2002 39 9 1414 1421 2-s2.0-0036569112 10.1016/S0735-1097(02)01773-4
48. Germanakis I., Anagnostatou N., Kalmanti M., Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxicity. Pediatric Blood and Cancer 2008 51 3 327 333 2-s2.0-48249098888 10.1002/pbc.21633
49. Fink F. M., Genser N., Fink C., Falk M., Mair J., Maurer-Dengg K., Hammerer I., Puschendorf B., Cardiac troponin T and creatine kinase MB mass concentrations in children receiving anthracycline chemotherapy. Medical and Pediatric Oncology 1995 25 3 185 189 2-s2.0-0029153153 10.1002/mpo.2950250305
50. Kismet E., Varan A., Ayabakan C., Alehan D., Portakal O., Büyükpamukçu M., Serum troponin T levels and echocardiographic evaluation in children treated with doxorubicin. Pediatric Blood and Cancer 2004 42 3 220 224 2-s2.0-1242294499
51. Wang T. J., Larson M. G., Levy D., Benjamin E. J., Leip E. P., Omland T., Wolf P. A., Vasan R. S., Plasma natriuretic peptide levels and the risk of cardiovascular events and death. New England Journal of Medicine 2004 350 7 655 663 2-s2.0-1442290043 10.1056/NEJMoa031994
52. Swedberg K., Cleland J., Dargie H., Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the task Force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. European Heart Journal 2005 26 11 1115 1140 10.1093/eurheartj/ehi204
53. Lipshultz S. E., Miller T. L., Scully R. E., Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. Journal of Clinical Oncology 2012 30 10 1042 1049 10.1200/JCO.2010.30. 3404
54. Tei C., Ling L. H., Hodge D. O., Bailey K. R., Oh J. K., Rodeheffer R. J., Tajik A. J., Seward J. B., New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac functiona study in normals and dilated cardiomyopathy. Journal of Cardiology 1995 26 6 357 366 2-s2.0-0029586902
55. Jurcut R., Wildiers H., Ganame J., D'hooge J., Paridaens R., Voigt J. U., Detection and monitoring of cardiotoxicitywhat does modern cardiology offer? Supportive Care in Cancer 2008 16 5 437 445 2-s2.0-41849088117 10.1007/s00520-007-0397-6
56. Tocchetti C. G., Ragone G., Coppola C., Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge. European Journal of Heart Failure 2012 14 2 130 137 10.1093/eurjhf/hfr165
57. Shankar S. M., Marina N., Hudson M. M., Hodgson D. C., Adams M. J., Landier W., Bhatia S., Meeske K., Ming H. C., Kinahan K. E., Steinberger J., Rosenthal D., Monitoring for cardiovascular disease in survivors of childhood cancer: report from the cardiovascular disease task force of the children's oncology group. Pediatrics 2008 121 2 e387 e396 2-s2.0-38849181123 10.1542/peds.2007-0575
58. Giesler G., Lenihan D. J., Durand J. B., The update on the rationale, use and selection of β -blockers in heart failure. Current Opinion in Cardiology 2004 19 3 250 253 2-s2.0-2442663793 10.1097/00001573-200405000-00010
59. Bristow M. R., β -Adrenergic receptor blockade in chronic heart failure. Circulation 2000 101 5 558 569 2-s2.0-0034620523
60. Remme W. J., Riegger G., Hildebrandt P., Komajda M., Jaarsma W., Bobbio M., Soler-Soler J., Scherhag A., Lutiger B., Rydén L., The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Cardiovascular Drugs and Therapy 2004 18 1 57 66 2-s2.0-3342943389 10.1023/B:CARD.0000025756.32499.6f
61. Cardinale D., Colombo A., Lamantia G., Colombo N., Civelli M., De Giacomi G., Rubino M., Veglia F., Fiorentini C., Cipolla C. M., Anthracycline-induced cardiomyopathy. Clinical relevance and response to pharmacologic therapy. Journal of the American College of Cardiology 2010 55 3 213 220 2-s2.0-73549087024 10.1016/j.jacc.2009.03.095
62. Lipshultz S. E., Lipsitz S. R., Sallan S. E., Simbre V. C., Shaikh S. L., Mone S. M., Gelber R. D., Colan S. D., Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. Journal of Clinical Oncology 2002 20 23 4517 4522 2-s2.0-0036895164 10.1200/JCO.2002.12.102
63. Bensky A. S., Covitz W., DuRant R. H., Primary care physicians' use of screening echocardiography. Pediatrics 1999 103 4 e40 2-s2.0-0033111742
64. Heidenreich P. A., Gubens M. A., Fonarow G. C., Konstam M. A., Stevenson L. W., Shekelle P. G., Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. Journal of the American College of Cardiology 2004 43 6 1019 1026 2-s2.0-1542498927 10.1016/j.jacc.2003.10.043
65. Albini A., Pennesi G., Donatelli F., Cammarota R., de Flora S., Noonan D. M., Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. Journal of the National Cancer Institute 2010 102 1 14 25 2-s2.0-74049097142 10.1093/jnci/djp440